Does adipose tissue inflammation drive the development of non-alcoholic fatty liver disease in obesity?

Clin Res Hepatol Gastroenterol. 2020 Sep;44(4):394-402. doi: 10.1016/j.clinre.2019.10.001. Epub 2020 Feb 7.

Abstract

Obesity, an increasingly common problem in modern societies, is associated with acquired metabolic disturbances. In this perspective, the development of insulin resistance is now recognized to be initiated by inflammation of the adipose tissue, but the events that lead to this inflammation are still vague. Furthermore, visceral adipose tissue plays a significant role in obesity pathophysiology and in its clinical effects, such as non-alcoholic fatty liver disease (NAFLD). Among the possible mechanisms linking NAFLD and obesity, we focused on Visfatin/NAMPT, mostly produced by macrophages infiltrated in adipose tissue and a biomarker of the inflammatory cascade affecting hepatic inflammation in NAFLD. We also addressed the signalling pathway triggered by the binding of VEGF-B to its receptor, which mediates lipid fluxes throughout the body, being a promising target to prevent ectopic lipid accumulation. We reviewed the available literature on the topic and we suggest a crosstalk between adipose tissue inflammation and NAFLD in order to provide new insights about the putative mechanisms involved in the development of NAFLD in the obesity context. A better understanding of the pathophysiological processes underlying NAFLD will allow the development of new therapeutic approaches.

Keywords: Adipose tissue inflammation; Molecular targets; Non-alcoholic fatty liver disease; Obesity.

Publication types

  • Review

MeSH terms

  • Adipose Tissue*
  • Humans
  • Inflammation / complications*
  • Non-alcoholic Fatty Liver Disease / etiology*
  • Obesity / complications*